Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain MetastasesAnna Maria Di Giacomo, Michele Maio, Massimo Guidoboni et al.|Clinical Cancer Research|2021Cited by 75
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Vanna Chiarion‐Sileni et al.|European Journal of Cancer|2024Cited by 39
1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trialAnna Maria Di Giacomo, Michele Maio, Michele Del Vecchio et al.|Annals of Oncology|2023Cited by 2